Skip to content
Menu

Kardigan, Inc. KARD

Full chart Compare
Set alert

Price alert · KARD

All alert types
11.54 USD -0.98 (-7.83%)

Regular-session close

11.54 0.00 0.00%

After hours · Nov 20, 4:38 PM ET

11.49 Day range 12.77
11.54 52-week range 25.90
YTD
-47.55%
1 year
-47.55%

 

No chart data for this range yet.
Market cap
1.08B
EPS (ttm)
-6.24
Shares out
93.60M
Forward P/E
-2.77
YTD return
-47.55%
1-year return
-47.55%
50-day average
14.54
200-day average
18.36
Enterprise value
712.78M
Volume
459.24K
Avg volume
621.15K
Open
12.09
Previous close
12.52
Day's range
11.49 – 12.77
52-week range
11.54 – 25.90
Analysts
Strong Buy
Price target
41.00 (+255.3%)
Earnings date
Feb 11, 2027

Key statistics

Price / book
1.89
Total cash
471.76M
Total debt
12.70M
Short % of float
7.13%

Fundamental scorecard

3 of 25 checks passed on KARD’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth No data
  • Profitability No data
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
KARD Revenue — quarterly 0
KARD Net income — quarterly -58.57M
KARD EPS — quarterly -0.64

Earnings

KARD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 2026-0.79———
Nov 12, 2026Sep 30, 2026-0.77997-0.64+0.14+17.95%
Aug 11, 2026Jun 30, 2026-0.67534-2.88-2.20-326.45%
May 26, 2026Mar 31, 2026—-3.86——

Upgrades / downgrades

KARD analyst upgrades and downgrades
DateFirmActionFromTo
Nov 4, 2026HC Wainwright & Co.init—Buy
Oct 29, 2026Cantor Fitzgeraldinit—Overweight
Oct 22, 2026Bairdinit—Outperform
Oct 16, 2026William Blairinit—Outperform
Oct 12, 2026UBSinit—Buy
Aug 25, 2026JP MorganmainOverweightOverweight

About Kardigan, Inc.

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
kardigan.bio

News

Your note

Sign in to keep a note on KARD — it syncs with the Stock Master app.

Insider holders

KARD insider holders
InsiderRelationLatest transactionDateShares held
ARCH VENTURE PARTNERS XIII, LLCBeneficial Owner of more than 10% of a Class of SecurityPurchaseJun 21, 20260
BERNS PAUL LDirector and Beneficial Owner of more than 10% of a Class of SecurityPurchaseJun 21, 20260
EDELBERG JAY M.D., PH.D.OfficerStock Award(Grant)Jun 16, 20264,643,170
GIANAKAKOS TOM ANASTASIOSChief Executive OfficerConversion of Exercise of derivative securityJun 16, 20260
HRTG GPE, L.L.CBeneficial Owner of more than 10% of a Class of SecurityPurchaseJun 21, 20260
JAHN BRIANNEChief Financial OfficerStock Award(Grant)Jun 16, 202679,640

Institution ownership

KARD institution ownership
Holder% heldSharesValueReported
HRTG GPE, LLC18.07%16,917,034195.22MSep 29, 2026
Arch Venture Management, Llc16.07%15,042,036173.59MSep 29, 2026
FMR, LLC10.47%9,801,465113.11MSep 29, 2026
Perceptive Advisors Llc8.76%8,200,66294.64MSep 29, 2026
T. Rowe Price Investment Management, Inc.4.59%4,298,39249.60MSep 29, 2026
Capital Research Global Investors3.87%3,617,88441.75MSep 29, 2026

Fund ownership

KARD fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc3.77%3,525,64840.69MSep 29, 2026
Fidelity Contrafund1.59%1,486,44317.15MSep 29, 2026
JPMorgan Trust II-JPMorgan Small Cap Growth Fund0.88%823,5989.50MJun 29, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.0.79%737,2338.51MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF0.79%736,2838.50MSep 29, 2026
TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust0.69%645,6847.45MJun 29, 2026